

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Robert C. Brunham
Appl'n. No. : 09/857,305
Filed : October 3, 2001
Title : TWO-STEP IMMUNIZATION PROCEDURE AGAINST CHLAMYDIA INFECTION
Grp./A.U. : 1645
Examiner : Khatol S. Shahnan-Shah
Docket No. : 1038-1153 MIS:jb
Date : October 6, 2003

RECEIVED

Via Facsimile (703) 305-3014

OCT 08 2003

Mail Stop Amendment
Commissioner of Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
U.S.A.

TECH CENTER 1600/2900

AMENDMENT

Dear Sir:

This Commission is submitted in respect to the Office Action of September 5, 2003.

The Examiner required an election of a single invention among three groups of claims. The applicants hereby elect the claim of Group II, namely claims 19 to 28, drawn to an attenuated bacterium. This election is made without prejudice to applicants right to file one or more divisional or continuation applications directed to the non-elected invention.

The election is made with traverse. The Examiner indicates that

"The special technical feature testing Groups I to III appears to be immunological activity of a major outer membrane protein (MOMP) of a strain of *Chlamydia*. However, Agabian et al teach immunological activity of the major outer membrane protein (MOMP) of a strain of *Chlamydia*.

Application No.: 09/857,305

2

"Therefore, the technical feature listing the invention of Groups I to II does not constitute a special technical feature as defined by PCT Rules 13.2, as it does not define a contribution over the prior art."

It is submitted that the Examiner is incorrect. It is true that Agabian et al disclose that MOMP is immunogenic. However, the reference shows only that *in vitro* recombinantly produced MOMP protein is immunogenic.

Applicants claims all involve the use of an attenuated bacteria harbouring a nucleic acid molecule encoding at least one immunoprotection-inducing *Chlamydia* protein or fragment thereof which generates a *Chlamydia* protein specific immune response, specifically MOMP. Claims 1 to 18 are directed to a two step immunization procedure and claims 29 to 40 are directed to one step immunization procedure using said attenuated bacteria while claims 19 to 28 are directed to bacteria itself.

The special feature linking the groups of the claims, therefore, is the attenuated bacteria and its use in DNA immunization. As is clear from the disclosure on page 8, lines 7 to 15, the transfected DNA (i.e. the nucleic acid molecule encoding MOMP) is not expressed in the bacterial vector and hence the attenuated bacterium could not be used to produce *in vitro* MOMP, as in Agabian et al. The expression of the DNA is effected when the bacterial vector has released the DNA into the appropriate host cells. After uptake of the bacterial vector by the host cells, the auxotrophic bacteria dies after a few rounds of division and the plasmid DNA then is released into the cytoplasm of the infected host cells and the encoded gene expressed in the host cell.

Accordingly, it is submitted that the restriction requirement is improper and that all claims should be examined in this application. Nevertheless, as noted above, applicants have elected the claims of Group II.

In addition, the Examiner required an election of species, indicating that, with respect to the claims of Group II, an election was required between the

Application No.: 09/857,305

3

Chlamydia species of claims 21 and 22. The applicants hereby elect the species of claim 22, namely *C. trachomatis*. Claims 19, 20 and 23 to 29 are generic thereto

The species election is made without prejudice to the applicants right, up-on the allowance of a generic claim, to consideration of claims to additional species which are written in dependent form or otherwise include the limitations of an allowed claim.

Respectfully submitted

Michael I. Stewart

Michael I. Stewart
Reg. No. 24,973

RECEIVED
CENTRAL FAX CENTER

OCT 06 2003

Toronto, Ontario, Canada
(416) 595-1155
FAX No. (416) 595-1163

OFFICIAL

(5)

Sim, Hughes, Ashton & McKay LLP

Barristers & Solicitors

Sim & McBurney
Patent & Trade Mark Agents

6th Floor, 330 University Avenue
Toronto, Ontario, Canada M5G 1R7

Tel. (416) 595-1155 • Fax (416) 595-1163

DATE: October 06, 2003

Application No.: 09/857,305

Our Ref: 1038-1153 MIS:jb

TO:	FAX #	PHONE #
USPTO Commissioner of Patents Examiner: Khatol S. Shahnan-Shah Art Unit : 1645	(703) 305-3014	(703) 308-3896

Total Number of Pages (Including This Page): 6

FROM: Michael I. Stewart / 239

COMMENTS:

OFFICIAL

RECEIVED
CENTRAL FAX CENTER

OCT 06 2003

RECEIVED
OCT 08 2003
TECH CENTER 1600/2900

We are transmitting from a Xerox Telecopier 7033, 7020 or Workcentre Pro 745 – Group 3 which are compatible with Groups 1 and 2 and fully automatic on a 24 hour basis. If any part of this message is received poorly or missing please call the telecopier operator immediately at (416) 595-1155.

Confidentiality Notice

This message is intended only for the use of the individual person or entity to which it is addressed and may contain information that is privileged and confidential. If the reader of this message is not the intended recipient or the agent responsible for delivering the message to the intended recipient, you are hereby notified that any disclosing, copying, distributing or the taking of any action in reliance on the contents of this communication is prohibited. If you have received this communication in error, please notify us immediately by telephone (call collect) and return the original message to us at the above address via the postal service. Thank you.

PTO/SB/21 (08-03)

Approved for use through 07/31/2008. OMB 0551-0031
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>		Application Number 09/857,305
		Filing Date October 3, 2001
		First Named Inventor Robert C. Brunham
		Art Unit 1645
		Examiner Name Khatoj S. Shahroo-Shah
Total Number of Pages in This Submission 5		Attorney Docket Number 1038-1153 MIS:jb

RECEIVED

OCT 08 2003

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence	<input checked="" type="checkbox"/> Other Enclosure(s) (see list below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Certificate of Transmission by Facsimile
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		Remarks
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

RECEIVED

CENTRAL FAX CENTER

OCT 06 2003

OFFICIAL

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Michael I. Stewart (Reg. No. 24,973)
Signature	<i>Michael I. Stewart</i>
Date	October 6, 2003

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 223 3-1450 on the

Typed or printed name	
Signature	
Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Received from < > at 10/6/03 9:33:15 AM [Eastern Daylight Time]

CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)

Applicant(s): Robert C. Brunham

Docket No.

1038-1143 MIS:jb

Serial No.
09/857,305Filing Date
October 3, 2001Examiner
Khatol S. Shahnan-ShahGroup Art Unit
1645

Invention: TWO-STEP IMMUNIZATION PROCEDURE AGAINST CHLAMYDIA INFECTION

I hereby certify that this Amendment
(Identify type of correspondence)
is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. (703) 305-014
on October 6, 2003
(Date)

Michael L. Stewart (Reg. No. 24,973)*(Typed or Printed Name of Person Signing Certificate)*Michael L. Stewart
(Signature)

RECEIVED
OCT 08 2003
TECH CENTER 1600/2900

Note: Each paper must have its own certificate of mailing.